Search

AB Science SA

Open

1.394 -0.71

Overview

Share price change

24h

Current

Min

1.342

Max

1.42

Key metrics

By Trading Economics

Income

-5.2M

Sales

515K

Profit margin

-1,005.243

Employees

36

EBITDA

-2.5M

Market Stats

By TradingEconomics

Market Cap

95M

Previous open

2.1

Previous close

1.394

Technical Score

By Trading Central

Confidence

Bearish Evidence

AB Science SA Chart

Past performance is not a reliable indicator of future results.

Related News

13 Jan 2026, 19:05 UTC

Major Market Movers

Travere Therapeutics Shares Fall After FDA Extends Filspari Review

13 Jan 2026, 23:41 UTC

Market Talk

Nikkei May Rise on Japan Election Hopes -- Market Talk

13 Jan 2026, 23:41 UTC

Market Talk

Global Equities Roundup: Market Talk

13 Jan 2026, 23:33 UTC

Market Talk

Gold Edges Higher, Supported by Ongoing Geopolitical Tensions -- Market Talk

13 Jan 2026, 23:13 UTC

Acquisitions, Mergers, Takeovers

JD Logistics Plans to Withdraw Listing Status of Deppon Logistics From Shanghai Stock Exchange

13 Jan 2026, 23:10 UTC

Acquisitions, Mergers, Takeovers

JD Logistics Makes Cash Offer to Buy Deppon Logistics Shares It Doesn't Already Own

13 Jan 2026, 23:03 UTC

Market Talk

Woodside's Sales Revenue Likely Fell 13% in 4Q -- Market Talk

13 Jan 2026, 21:50 UTC

Acquisitions, Mergers, Takeovers

Netflix Preparing to Make Warner Bid All-Cash -- WSJ

13 Jan 2026, 21:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Basic Materials Roundup: Market Talk

13 Jan 2026, 21:20 UTC

Acquisitions, Mergers, Takeovers

Versant Media: Katz Will Continue to Lead Day-To-Day Ops of FTN

13 Jan 2026, 21:20 UTC

Acquisitions, Mergers, Takeovers

Versant Media: Transaction Strengthens Distribution Footprint and Expands Free-To-Watch Portfolio >VSNT

13 Jan 2026, 21:20 UTC

Acquisitions, Mergers, Takeovers

Versant Media: Jonathan Katz, FTN's Founder, Has Joined VERSANT, Reporting to David Pietrycha >VSNT

13 Jan 2026, 21:15 UTC

Acquisitions, Mergers, Takeovers

VERSANT Completes Acquisition Of Free TV Networks >VSNT

13 Jan 2026, 21:08 UTC

Acquisitions, Mergers, Takeovers

Array Digital Infrastructure Declares Special Dividend of $10.25 >AD

13 Jan 2026, 20:39 UTC

Market Talk

Silver Settles at Another New High -- Market Talk

13 Jan 2026, 20:21 UTC

Market Talk

Oil Futures Extend Rally On Rising Iran Tensions -- Market Talk

13 Jan 2026, 20:17 UTC

Market Talk

U.S. Natural Gas Edges Up on Coming Weather -- Market Talk

13 Jan 2026, 19:08 UTC

Acquisitions, Mergers, Takeovers

Super Micro Computer Is an AI Winner. Sell the Stock Anyway, Goldman Sachs Says. -- Barrons.com

13 Jan 2026, 19:03 UTC

Earnings

Double-Digit Earnings Growth Could Continue. It Still Might Not Satisfy Investors. -- Barrons.com

13 Jan 2026, 18:50 UTC

Earnings

JPMorgan's Unusual Quarter Weighs on Shares. How Apple Plays a Role. -- Barrons.com

13 Jan 2026, 17:54 UTC

Market Talk

UnitedHealth Reaffirms 2025 Guidance After Senate Report -- Market Talk

13 Jan 2026, 17:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Global Equities Roundup: Market Talk

13 Jan 2026, 17:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Netflix Will Be a Winner No Matter How Warner Saga Ends -- Market Talk

13 Jan 2026, 17:49 UTC

Market Talk

Analysts Call For Potential Record Ethanol Output -- Market Talk

13 Jan 2026, 17:38 UTC

Market Talk

Merck CEO Sees $5B Market for Cidara's Flu Antiviral -- Market Talk

13 Jan 2026, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

13 Jan 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

13 Jan 2026, 17:20 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Basic Materials Roundup: Market Talk

13 Jan 2026, 17:19 UTC

Market Talk

Credit Cards Present Opportunity, Potential Obstacle for JPMorgan -- Market Talk

13 Jan 2026, 17:15 UTC

Market Talk

Merck CEO Sees Eventual Growth After Keytruda Exclusivity Expires -- Market Talk

AB Science SA Forecast

Rating Consensus

By TipRanks

0 ratings

0

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

1.426 / 1.448Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Bullish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About AB Science SA

AB Science S.A., a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. The company's lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer's disease, and metastatic castrate-resistant prostate cancer, as well as in Phase II clinical trial to treat Covid-19. It also developing AB8939, a microtubule destabiliser for acute myeloid leukemia. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.
help-icon Live chat